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Background: Indication to implantable cardioverter deﬁbrillator (ICD) for primary prevention of sudden
death relies on left ventricular ejection fraction (LVEF). We measured the proportion of patients in whom
indication to ICD persisted at the time of generator replacement (GR) and searched for predictors of
appropriate therapies after GR.
Methods: We identiﬁed all consecutive patients who had received an ICD at our hospital, for LVEF 35%
and no previous arrhythmias or unexplained syncope. Then, we included the 166 patients who outlived
their ﬁrst device and underwent GR.
Results: At the time of GR (mean follow-up 59 ± 20 months), ICD indication (i.e. LVEF 35% or previously
treated ventricular arrhythmias) persisted in 114 (69%) patients. After GR, appropriate ICD therapies were
delivered in 30 (26%) patients with persistent ICD indication and in 12 (23%) of the remaining patients
(p ¼ 0.656). Nonetheless, the annual rate of therapies was higher in the ﬁrst group (1.08 versus 0.53
events/year; p < 0.001), as well as the rate of inappropriate therapies (0.03 versus 0 events/year;
p ¼ 0.031). The only independent predictor of appropriate ICD therapies after GR was the rate of shocks
received before replacement (Hazard Ratio: 1.41; 95% conﬁdence interval: 1.01e1.96; p ¼ 0.041).
Conclusion: In heart failure with reduced LVEF, ICD indication persisted at the time of GR in 69% of
patients. However, even in the absence of persistent ICD indication at GR, the risk of recurrence of
arrhythmic events was not null.
Copyright © 2016, Indian Heart Rhythm Society. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Currently, the selection of candidates for implantable car-
dioverter deﬁbrillator (ICD) implantation for primary prevention of
sudden cardiac death relies mainly on left ventricular ejection
fraction (LVEF) evaluation at the time of pre-implantation screening
[1].
Previous studies have shown that a proportion of patients
implanted for primary prevention of sudden death improve their.O.U. Maggiore della Carita,
ara.it (E. Occhetta).
Rhythm Society.
ociety. Production and hosting by
, et al., Persistence of ICD ind
ubsequent ICD therapies, IndLVEF after ICD implantation [2e6], especially if treated with cardiac
resynchronization therapy ICD (CRT-D).
As a substantial proportion of ICD recipients outlive their ﬁrst
device and must undergo generator replacement, some authors
questioned the appropriateness of ICD replacement when primary
prevention indication does not persist and no ventricular arrhyth-
mias were documented during follow-up [7]. We hypothesized that
patients without persistent ICD indication at device replacement
could be at lower risk of ICD therapies after replacement.
We sought to determine the persistence of ICD indication at the
time of generator replacement in patients who had received an ICD
for primary prevention of sudden cardiac death, and tomeasure the
rate of ICD therapies after replacement. In addition, we investigated
the existence of predictors of appropriate therapies after generatorElsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
ication at the time of replacement in patients with initial implant for
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Fig. 1. Study ﬂow diagram.
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2. Materials and methods
The study was approved by our internal committee for Human
Research. At the time of implantation, patients gave informed
consent for future use of de-identiﬁed data.
2.1. Patient selection, pacemaker implantation and follow-up
We prospectively collected data about all consecutive adult
patients who underwent ICD implantation from 2000 to 2015 at
our hospital. For the aim of present analysis, we retrospectively
evaluated patients who received ICD for primary prevention of
sudden cardiac death. All patients were implanted according to the
then contemporary international guidelines and underwent a trial
of optimized medical therapy and revascularization before
receiving ad ICD. Thus, we identiﬁed patients with LVEF 35% and
no documentation of previous arrhythmias or unexplained syncope
at the time of implantation. Of them, we included in analysis all
patients who outlived their ﬁrst device and underwent generator
replacement. Data collection included patient characteristics and
LVEF value at baseline and at replacement. LVEF was assessed by
Simpson's equation using the apical four-chamber view. Data about
delivery of appropriate therapies for ventricular arrhythmia were
collected from device interrogation records. Spontaneous
arrhythmic episodes detected by the device were validated by 2
independent electrophysiologists blinded to the patient outcome. If
a consensus could not be reached, a third electrophysiologist was
involved in episode review. Device implantation and replacement
were performed according to standard clinical practice and opti-
mization of ICD parameters and pharmacological treatments were
based on clinical evaluation by the attending physicians. During
follow-up, patients underwent standard transthoracic echocardio-
graphic examination every 6 months and before device
replacement.
We measured the proportion of patients with persistent ICD
indication at the time of generator replacement. In particular, we
identiﬁed those patients with LVEF 35% or who received appro-
priate ICD therapies before replacement. Moreover, we investigated
the existence of predictors of appropriate therapies after generator
replacement.
2.2. Statistical analysis
Continuous datawere expressed as means ± standard deviation.
Categorical data were expressed as percentages. Differences be-
tween mean data were compared by a t-test for Gaussian variables
and by the Mann-Whitney-Wilcoxon nonparametric test for non-
Gaussian variables. Differences in proportions were compared by
a chi-square analysis. Event rates were summarized by constructing
KaplaneMeier curves. The log-rank test was applied to evaluate
differences between trends. Cox regression was used to analyze
possible predictors of appropriate ICD therapies or shocks after
replacement. The rates of events were analyzed by using the
Comparison of Incidence Rates (Large Sample) Test. A P value <0.05
was considered signiﬁcant for all tests. All statistical analyses were
performed by means of STATISTICA software, version 7.1 (StatSoft,
Inc.).
3. Results
3.1. Study population and baseline evaluation
From 2000 to 2015, 1130 consecutive patients underwent ICDPlease cite this article in press as: Dell’Era G, et al., Persistence of ICD ind
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10.1016/j.ipej.2016.11.008implantation at our hospital. Of them, 166 underwent one or more
generator replacements during follow-up and had LVEF 35% and
no documentation of previous arrhythmias or unexplained syncope
at the time of ﬁrst implantation (Fig. 1). Table 1 shows baseline
clinical variables at the time of ﬁrst implantation.3.2. Follow-up (from ICD implantation to ﬁrst replacement)
The patients in analysis underwent generator replacement for
battery depletion after a mean follow-up of 59 ± 20 months.
Twenty patients previously implanted with single- or dual-
chamber ICD developed CRT indications and received a CRT-D de-
vice at replacement. At the time of device removal, ICD in-
terrogations revealed appropriate therapies for ventricular
arrhythmia in 48 patients (0.74 events/year in the overall group). In
particular, 28 patients had received appropriate shock therapies
(0.13 events/year). Moreover, 21 patients had received inappro-
priate therapies (0.03 events/year) (Fig. 2).
At the time of replacement, the mean LVEF was 33 ± 11% and 64
patients showed LVEF >35% (mean 44 ± 7% in this subgroup). In
particular, 9 patients showed LVEF >50%, and 20% of patients with
ICD alone (no CRT) showed amarked increase in EF (from 27± 5% to
43 ± 6%, p < 0.001). We therefore identiﬁed a persistent ICD indi-
cation for prevention of sudden death in 114 (69%) patients. The
clinical parameters of patients with persistent and non-persistent
ICD indication are reported in Table 2. More frequently, patients
with persistent ICD indicationweremale, had ischemic disease, and
did not receive CRT-D. Persistent ICD indications were reported in
57 (60%) patients initially implanted with CRT-D devices, and in 57
(80%) patients initially implanted with single- or dual-chamber
ICDs (p ¼ 0.005).ication at the time of replacement in patients with initial implant for
ian Pacing and Electrophysiology Journal (2016), http://dx.doi.org/
Table 1
Demographics and clinical parameters at the time of ﬁrst implantation.
Baseline N ¼ 166
Male gender, n (%) 135 (81)
Age, years 66 ± 10
Ischemic heart disease, n (%) 90 (54)
NYHA class
Class I, n (%) 6 (3)
Class II, n (%) 81 (49)
Class III, n (%) 76 (46)
Class IV, n (%) 3 (2)
CRT deﬁbrillator, n (%) 95 (57)
LV ejection fraction, % 25 ± 6
History of atrial ﬁbrillation
Paroxysmal, n (%) 36 (22)
Persistent, n (%) 26 (16)
Permanent, n (%) 30 (18)
Class III antiarrhythmic use, n (%) 26 (16)
NYHA: New York Heart Association; LV: left ventricular.
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After ICD replacement, patients were followed for amean period
of 25 ± 23 months. In this second phase, appropriate therapies for
ventricular arrhythmia were delivered in 42 patients (0.86 events/Fig. 2. Number of patients (pts) with therapies before ﬁrst ICD replacement. Number of patie
28 patients; see text for details).
Table 2
Clinical parameters and therapy at the time of ﬁrst implantation and replacement.
Persistent ICD indication (114)
First Implantation
Male gender, n (%) 98 (86)
Age, years 67 ± 9
Ischemic heart disease, n (%) 71 (62)
NYHA class III-IV, n (%) 51 (45)
CRT deﬁbrillator, n (%) 57 (50)
LV ejection fraction, % 25 ± 6
History of atrial ﬁbrillation
Paroxysmal, n (%) 26 (23)
Persistent, n (%) 18 (16)
Permanent, n (%) 19 (17)
Class III antiarrhythmic use, n (%) 15 (13)
*: p < 0.05 versus Persistent.
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10.1016/j.ipej.2016.11.008year in the overall group), and 21 patients received appropriate
shock therapies (0.17 events/year). Moreover, 7 patients received
inappropriate therapies (0.02 events/year). In particular, appro-
priate therapies were delivered in 30 (26%) patients with persistent
ICD indication and in 12 (23%) of the remaining patients
(p¼ 0.656). Nonetheless, the annual rate of therapies was higher in
the ﬁrst group: 1.08 events/year versus 0.53 events/year
(p < 0.001). Appropriate shock therapies were delivered in 14 (12%)
patients with persistent ICD indication and in 7 (13%) of the
remaining patients (p ¼ 0.832). The annual rate of shock was
comparable between groups (0.17 events/year versus 0.17 events/
year; p ¼ 0.971), while the rate of inappropriate therapies was
higher in the ﬁrst group (0.03 events/year versus 0 events/year;
p¼ 0.031). In particular, appropriate ICD therapies were reported in
3 patients with LVEF >50% at replacement.
The KaplaneMeier analysis of time from generator replacement
to ﬁrst appropriate therapy, stratiﬁed by persistence or non-
persistence of indication to ICD, showed no differences between
groups (Fig. 3).
At Cox regression analysis (Table 3), the only independent pre-
dictor of appropriate ICD therapies after replacement was the rate
of shocks received before replacement (Hazard Ratio: 1.41; 95%
conﬁdence interval: 1.01e1.96; p ¼ 0.041).nts with at least one appropriate shock is marked in bold in different subgroups (total:
Non-persistent ICD indication (52)
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Fig. 3. KaplaneMeier estimates of time from generator replacement to ﬁrst appropriate therapy, stratiﬁed by persistence or non-persistence of primary prevention indication to
ICD.
Table 3
Predictors of appropriate therapies and shocks after generator replacement (p for univariate analysis).
All therapies Shocks
HR 95% CI p HR 95% CI p
Male gender 1.50 0.63e3.55 0.363 2.60 0.61e11.10 0.199
Age 1.00 0.97e1.04 0.755 0.99 0.95e1.03 0.647
Ischemic etiology 1.22 0.66e2.25 0.533 1.42 0.59e3.41 0.442
CRT deﬁbrillator (ﬁrst implantation) 1.18 0.63e2.19 0.605 0.86 0.37e2.04 0.740
CRT deﬁbrillator (after replacement) 1.09 0.57e2.10 0.801 1.21 0.47e3.11 0.694
LV ejection fraction (replacement) 0.99 0.97e1.02 0.764 0.99 0.96e1.04 0.940
NYHA class 0.93 0.56e1.55 0.777 1.04 0.50e2.17 0.913
History of paroxysmal atrial ﬁbrillation 2.01 0.98e3.94 0.081 2.09 0.85e5.17 0.111
History of persistent atrial ﬁbrillation 1.07 0.48e2.141 0.868 0.88 0.26e2.97 0.880
History of permanent atrial ﬁbrillation 0.92 0.42e1.98 0.827 1.53 0.60e3.94 0.377
Class III antiarrhythmic use 1.35 0.65e2.81 0.429 1.37 0.50e3.73 0.538
Appropriate therapies before replacement or LVEF 35% 1.68 0.86e3.28 0.133 1.31 0.53e3.25 0.563
Rate of appropriate therapies before replacement 1.03 0.99e1.06 0.057 1.02 0.98e1.07 0.263
Rate of shocks before replacement 1.41 1.01e1.96 0.041 1.31 0.83e2.06 0.256
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In the present study we demonstrated that the ICD indication
for prevention of sudden cardiac death persisted at the time of
generator replacement in 69% of patients who had received a pri-
mary prevention ICD in the setting of heart failure with reduced
LVEF. Nonetheless, the persistence of indication was not associated
with a higher risk of further appropriate ICD therapies. Indeed, the
recurrence of arrhythmic events was only associated with a higher
rate of shocks delivered before replacement.
Currently, the selection of ICD candidates relies mainly on LVEF
evaluation at the time of pre-implantation screening [1], as reduced
LVEF was the principal inclusion criterion in trials for primary
prevention of sudden cardiac death. Nonetheless, although no
other strong and reliable tools are available at the moment, in the
last ten years growing evidence is accumulating that LVEF is not an
optimal risk discriminator [8]. Indeed, LVEF has a limited speciﬁcity
for the underlying risk, meaning that a reduced LVEF is a risk factor
not only for sudden but also for non-sudden death [9,10]. Moreover,
only relatively few patients with reduced LVEF beneﬁt from an ICD,
and indeed the number of ICDs needed to prevent a death over 45Please cite this article in press as: Dell’Era G, et al., Persistence of ICD ind
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In addition, strong evidences are missing about patients with EF
recovery after optimal therapy; in this setting ICD implantation is
not usually recommended (a waiting time of 1e3months is usually
warranted before SCD prophylaxis [1]), because early ICD implan-
tation showed no beneﬁt on overall mortality. However, some
Authors proposed early implantation or bridge therapy with
wearable deﬁbrillator in patients at “high risk” (a poorly deﬁned
category) because SCD is not null and, after EF recovery or when a
borderline EF is observed, a residual risk may persist in selected
patients (e.g. the ones with anatomical substrate for ventricular
arrhythmias) [12].
Our analysis conﬁrmed that LVEF alone is a poor risk stratiﬁer
and that, even in the absence of documented ventricular arrhyth-
mias, a subsequent life threatening arrhythmic event cannot be
excluded in patients with improved LVEF at follow-up (and, maybe,
even before primary prevention implant). We identiﬁed a large
proportion of patients implanted for primary prevention of sudden
cardiac death who had no ICD interventions and who improved
their LVEF to more than 35% at the time of generator replacement.
Although we noticed a lower rate of appropriate ICD therapies inication at the time of replacement in patients with initial implant for
ian Pacing and Electrophysiology Journal (2016), http://dx.doi.org/
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events was comparable in the two groups, and we also reported
arrhythmic events among patients who showed full recovery of
LVEF (i.e. >50%). Therefore, although the discontinuation of ICD
therapy in these patients may be tempting from an economic point
of view, as well as the possibility of downgrading a CRT-D to a CRT
pacemaker in patients requiring biventricular pacing, the risk of
sudden cardiac death remains not null. Nonetheless, although the
potential complications associatedwith the replacement procedure
are not negligible [13], we showed a lower rate of inappropriate
therapies in patients with no persistent ICD indication, and thus a
potentially lower negative impact on the outcome and the quality
of life.
In the perspective of discontinuing ICD therapy, one additional
open question concerns the management of the depleted device:
leaving it in place, removing the generator or the complete system,
using the ICD lead for right ventricular pacing in case of concomi-
tant CRT or pacing indications. Every option is associated with
different potential risks and should be carefully evaluated. Of
course, the adoption of modern technologies, such as the totally
subcutaneous ICD, would allow an easier management of possible
system removal.
Looking at the question from a different perspective, the prob-
lem of changes in indication at the time of ICD replacement can be
solved by decreasing the proportion of ICD recipients who outlive
their ﬁrst device. In our study, the mean longevity of ICDs
implanted over the last 15 years was approximately 5 years. As
Hauser suggested in 2005 [14], a 10-years battery would allow to
provide an ICD that lasts a lifetime in the majority of patients, and
recent data seem to show thatmodern battery technology (e.g. high
capacity cells, highly efﬁcient chemistry) has ﬁnally reached this
goal [15].
4.1. Limitations
The ﬁrst limitation of the present study is the retrospective
design of the analysis. However, all the patients included were
consecutive. Secondly, the number of patients in analysis was
relatively small. Thirdly, several clinical variables or comorbid
conditions at baseline and at replacement were not considered in
our analysis of potential predictors. Fourthly, the long duration of
the enrollment period may have impacted the results, as the im-
plantation criteria and the ICD programming may have changed
over time. However, the studywas carried out in a single center, the
operators in charge of patient selection, device implantation and
clinical management did not change during the study period. Lastly,
the therapies delivered by the ICD are only a surrogate endpoint
andmay not be necessarily considered as prevented sudden cardiac
death, as episodes of nonsustained ventricular tachycardia
frequently terminate spontaneously [16]. However, this approach
was previously adopted by other Authors [5,6] and, in our opinion,
is the only feasible in a retrospective setting.
5. Conclusions
In our study we did not ﬁnd sensitive predictors of recurrent
arrhythmias after generator replacement, in patients who had
received an ICD for primary prevention of sudden death in the
setting of heart failure with reduced LVEF. Therefore, although
current criteria for ICD indication did not persist at the time ofPlease cite this article in press as: Dell’Era G, et al., Persistence of ICD ind
primary prevention indication: Effect on subsequent ICD therapies, Ind
10.1016/j.ipej.2016.11.008replacement in about 30% of patients, in our opinion ICD therapy
discontinuation seems not perfectly safe. Larger prospective trials
are needed to identify reliable risk factors at the time of ﬁrst ICD
implantation and replacement.
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